Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to assets ratio high or low?
The debt to assets ratio of 0.35% is 92% below its 5-year average of 4.37%, near the low end of its 5-year range (0.03%–9.63%).
As of the fiscal period ended Tuesday, June 30, 2026. 75.94% below its 12-month average of 1.46%.
Reported quarterly debt to assets ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 0.35%.
DEBT TO ASSETS RATIO
0.35%
DEBT TO ASSETS RATIO AVG TTM
1.46%
DEBT TO ASSETS RATIO AVG 3Y
2.56%
DEBT TO ASSETS RATIO AVG 5Y
4.37%
DEBT TO ASSETS RATIO AVG 10Y
2.17%
DEBT TO ASSETS RATIO AVG 15Y
N/A
DEBT TO ASSETS RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-75.94%
CURRENT VS 3Y AVG
-86.24%
CURRENT VS 5Y AVG
-91.95%
CURRENT VS 10Y AVG
-83.80%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.10%
median of 592 covered companies
CURRENT VS SECTOR MEDIAN
+252.00%
vs the sector median at left
Enlivex Therapeutics Ltd.
Market Cap
$5.99M
Debt to Assets Ratio
0.35%
TTM Avg
1.46%
3Y Avg
2.56%
5Y Avg
4.37%
Market Cap
$6.07M
Debt to Assets Ratio
0.05%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$5.87M
Debt to Assets Ratio
0.06%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$5.55M
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$6.58M
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$6.58M
Debt to Assets Ratio
0.07%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | DEBT TO ASSETS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Enlivex Therapeutics Ltd. (ENLV) | $5.99M | 0.35% | 1.46% | 2.56% | 4.37% |
| Cardio Diagnostics Holdings, Inc. (CDIO)vs › | $6.07M | 0.05% | N/A | N/A | N/A |
| Cuprina Holdings (Cayman) Limited Class A Ordinary Shares (CUPR)vs › | $5.87M | 0.06% | N/A | N/A | N/A |
| Lucyd, Inc (LUCY)vs › | $5.84M | 0.01% | N/A | N/A | N/A |
| Biomerica, Inc. (BMRA)vs › | $6.21M | 0.28% | N/A | N/A | N/A |
| Femasys Inc. (FEMY)vs › | $6.28M | 0.39% | N/A | N/A | N/A |
| Acurx Pharmaceuticals, Inc. (ACXP)vs › | $5.55M | 0.00% | N/A | N/A | N/A |
| Enveric Biosciences, Inc. (ENVB)vs › | $6.58M | 0.00% | N/A | N/A | N/A |
| Ensysce Biosciences, Inc. (ENSC)vs › | $6.58M | 0.07% | N/A | N/A | N/A |
| Lunai Bioworks Inc. (LNAI)vs › | $5.37M | 0.14% | N/A | N/A | N/A |
Debt/Assets
0.4%
Debt/Equity
0.00
Current Ratio
119.39
Interest Coverage
-1153.8x
Formula: Debt/Assets = Total Debt / Total Assets × 100
Debt/Assets vs Debt/Equity:
Industry context matters: Capital-intensive industries (utilities, real estate) typically have higher Debt/Assets ratios than tech companies.
Debt/Assets ratio shows what percentage of a company's assets are financed by debt. Compare the current value with the historical chart and peer group to understand leverage over time.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO ASSETS RATIO |
|---|---|
| 2026-06-30 | 0.35% |
| 2025-12-31 | 0.03% |
| 2025-09-30 | 3.35% |
| 2025-06-30 | 2.12% |
| 2025-03-31 | 2.09% |
| 2024-12-31 | 1.93% |
| 2024-09-30 | 2.57% |
| 2024-06-30 | 2.62% |
| 2024-03-31 | 2.99% |
| 2023-12-31 | 2.80% |
| 2023-09-30 | 9.63% |
| 2023-06-30 | 8.24% |
| 2023-03-31 | 7.79% |
| 2022-12-31 | 7.17% |
| 2022-09-30 | 7.26% |
| 2022-06-30 | 6.82% |
| 2022-03-31 | 6.68% |
| 2021-12-31 | 6.31% |
| 2021-09-30 | 6.10% |
| 2021-06-30 | 0.65% |
| 2021-03-31 | 0.68% |
| 2020-12-31 | 0.50% |
| 2020-09-30 | 2.04% |
| 2020-06-30 | 1.01% |
| 2020-03-31 | 0.32% |
| 2019-12-31 | 0.70% |
| 2019-09-30 | 2.01% |
| 2019-06-30 | 1.97% |
| 2019-03-31 | 1.51% |
| 2018-12-31 | 0.00% |
| 2018-09-30 | 0.00% |
| 2018-06-30 | 0.00% |
| 2017-12-31 | 0.00% |
| 2017-09-30 | 0.00% |
| 2017-06-30 | 0.00% |
| 2017-03-31 | 0.00% |
| 2016-12-31 | 0.00% |
| 2016-09-30 | 0.00% |
| 2016-06-30 | 0.00% |
| 2016-03-31 | 0.00% |
| 2015-12-31 | 0.00% |
| 2015-09-30 | 0.00% |
| 2015-06-30 | 0.00% |
| 2015-03-31 | 0.00% |
| 2014-12-31 | 0.00% |
| 2014-09-30 | 0.00% |
| 2014-06-30 | 0.00% |
| 2013-12-31 | 0.00% |
